Vanqua Bio is helping usher in a new era of hope for the millions of people living with neurodegenerative diseases. Our unique drug-development approach is designed to overcome longstanding challenges in the neuroscience field by capitalizing on the power of human genetics to identify genes that cause or increase the risk of neurodegenerative disease. We leverage novel, proprietary research tools and in vitro modeling of disease, based on patient-derived neuronal cells, to develop transformative therapies that slow or stop the progression of Parkinson’s disease (PD), Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and Gaucher disease (GD). 

Biotechnology

Vanqua Bio

Jim Sullivan

Jesse Cedarbaum

Omer Siddiqui

Daniel Ysselstein

Jack Beyer

Kevin Hunt

Board of Directors

Leadership Team

CEO and Executive Team

Vanqua Bio

Org chart

Teams

Board of Directors

Leadership Team

CEO and Executive Team

Similar companies